Translational Pharmaceutics

Our Translational Pharmaceutics™ platform allows flexibility and precision to be built into your early clinical programmes. In contrast to conventional approaches, this platform enables real-time responses to clinical data to drive selection of the formulation type or composition for the next clinical dosing period. This ensures provision of ‘fit for purpose’ formulations. 

This platform has a number of benefits, including the ability to enhance the speed, success and value of pivotal Phase I clinical studies. Our Translational Pharmaceutics platform also ensures satisfactory exposure of the drug product to humans in FIH studies, demonstrating safety and tolerability. It expedites a formulations’ transition to a drug product capable of demonstrating PoC and being suitable for full development.

The benefits of this platform in contrast to the traditional approach are summarised below: